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Abstract
The present study was undertaken to investigate the interaction of anionic cephalosporins cefixime, ceftibuten, and
.  .  .cefdinir with the renal peptide transporter PEPT 2 and the intestinal peptide transporter PEPT 1 using four different
experimental model systems. In the first approach, the human colon carcinoma cell line Caco-2 which expresses PEPT 1
and the SHR rat kidney cell line SKPT which expresses PEPT 2 were used. The uptake of the dipeptide Gly-Sar mediated
by PEPT 1 or PEPT 2 in these cells was inhibited significantly by the anionic cephalosporins, with the following order of
potency: ceftibuten)cefixime)cefdinir. The inhibition was competitive in nature. Even though the order of potency was
the same for PEPT 1 and PEPT 2, PEPT 1 exhibited much lesser sensitivity to inhibition than PEPT 2. In the second
approach, the cloned human PEPT 1 and PEPT 2 were functionally expressed in HeLa cells following which the cells were
used to study the interaction of anionic cephalosporins with PEPT 1 and PEPT 2. Again, Gly-Sar uptake mediated by the
human PEPT 1 and PEPT 2 in HeLa cells was found to be inhibited by the anionic cephalosporins with the same order
potency as in Caco-2 and SKPT cells. In the third approach, brush border membrane vesicles isolated from rat kidneys were
employed. In this approach also it was found that PEPT 2-mediated Gly-Sar uptake was inhibited by cefixime and
ceftibuten. In the fourth approach, the human PEPT 1 was expressed in Xenopus lae˝is oocytes and PEPT 1-mediated
transport of ceftibuten was investigated directly by electrophysiological methods. Ceftibuten evoked inward currents in
PEPT 1-expressing oocytes but not in water-injected oocytes, showing that the transport of the anionic cephalosporin via
PEPT 1 is associated with transfer of positive charge. The ceftibuten-evoked currents were saturable with respect to
ceftibuten concentration and were markedly dependent on membrane potential. It is concluded that anionic cephalosporins
 .  .interact with the peptide transporters expressed in the intestine PEPT 1 as well as in the kidney PEPT 2 .
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1. Introduction
The peptide transporters expressed in the brush
border membrane of the intestinal and renal epithelial
cells are responsible for the absorption of small pep-
w xtides which consist of two or three amino acids 1–5 .
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These transporters are energy-dependent, driven by a
transmembrane Hq gradient, and catalyze the co-
q w xtransport of the peptide substrates with H 6–8 . In
addition to the endogenously occurring dipeptides
and tripeptides, several pharmacologically active ex-
ogenous compounds which possess peptide-like
chemical structures are also accepted as substrates by
w xthe intestinal and renal peptide transporters 9–11 .
These compounds include the b-lactam antibiotics,
cephalosporins and penicillins, angiotensin-convert-
ing enzyme inhibitors, renin inhibitors, and the anti-
neoplastic agent bestatin. The peptide transporters are
important determinants of the therapeutic efficacy of
these peptidomimetic drugs by influencing their
bioavailability and circulatory half-life.
Among the cephalosporin antibiotics, some are
zwitterionic e.g., cephalexin, cefadroxil, and cefa-
. clor while some are anionic e.g., cefixime,
.ceftibuten, and cefdinir . It has been well established
that zwitterionic cephalosporins are effectively trans-
ported by intestinal as well as renal peptide trans-
w xporters 12–16 . However, it is not clear whether
anionic cephalosporins are effective substrates for
both of these peptide transporters. Studies from sev-
eral laboratories have shown that the anionic
cephalosporins cefixime, cefdinir and ceftibuten are
transported by the intestinal peptide transport system
w x17–25 . But there is controversy regarding the inter-
action of these anionic cephalosporins with the renal
w xpeptide transport system. Tamai et al. 26 have
demonstrated, with isolated renal brush border mem-
brane vesicles, that cefixime is not recognized as a
substrate by the renal system, whereas Naasani et al.
w x27–29 have shown, using the same experimental
approach, that ceftibuten is a substrate for the renal
system. Cefixime and ceftibuten are structurally very
similar and both are dianionic. Therefore, it is sur-
prising that the studies by Tamai et al. and by
Naasani et al. have led to different conclusions with
regard to whether or not anionic cephalosporins are
substrates for the renal peptide transport system. It
has to be pointed out here that the peptide trans-
porters are not the only transport systems available
for the absorption of anionic cephalosporins in the
intestine and the kidney. The monocarboxylate trans-
porter present in the intestine has been shown to
participate in the absorption of the monoanionic
w xcephalosporin cefdinir 20 . However, this particular
system is most likely restricted to monoanionic
cephalosprins. Dianionic cephalosporins such as ce-
fixime and ceftibuten are not likely to be effective
substrates for the monocarboxylate transporter.
The purpose of the present investigation was to
study the interaction of anionic cephalosporins with
the intestinal and renal peptide transporters using four
different approaches. In the first approach, cultured
cell lines of intestinal and renal origin which constitu-
tively express Hq-coupled peptide transport activity
were used. Caco-2 cells are of human intestinal origin
and are known to possess a low affinity Hqrpeptide
 . w xcotransport system PEPT 1 30 . SKPT cells are of
rat renal origin and are known to possess a high
q  .affinity H rpeptide cotransport system PEPT 2
w x31 . In the second approach, cloned human intestinal
and renal Hqrpeptide cotransporters, namely PEPT 1
w x w x32 and PEPT 2 33 respectively, were functionally
expressed in HeLa cells which were then used in the
described studies. In the third approach, brush border
membrane vesicles isolated from rat kidneys were
employed. In each of these approaches, peptide trans-
port activity was measured by the uptake of the
 .dipeptide glycylsarcosine Gly-Sar in the presence of
an inwardly directed Hq gradient and the interaction
of anionic cephalosporins with the peptide trans-
porters was investigated by analyzing the ability of
these compounds to compete with Gly-Sar for the
uptake process. In the fourth approach, the cloned
human PEPT 1 was functionally expressed in Xeno-
pus lae˝is oocytes and the PEPT 1-mediated trans-
port of the anionic cephalosporin ceftibuten was di-
rectly investigated by electrophysiological ap-
proaches. The results of the investigation clearly
show that anionic cephalosporins are transported by
intestinal as well as renal peptide transport systems.
2. Materials and methods
2.1. Materials
w 14 x w 14 x 2- C Glycyl 1- C sarcosine specific radioac-
.tivity, 109 mCirmmol was custom synthesized by
 .Cambridge Research Biochemicals Cleveland, UK .
Cell culture media were purchased from Life Tech-
 .nologies, Inc. Gaithersburg, MD, USA . Fetal bovine
serum, dexamethasone and apotransferrin were ob-
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 .tained from Sigma St. Louis, MO, USA . Cefixime,
ceftibuten and cefdinir were generous gifts from Dr.
 .Akira Tsuji Kanazawa University, Kanazawa, Japan .
The rat renal proximal tabular cell line SKPT, origi-
nating from SHR rat kidney, was provided by Dr.
Ulrich Hopfer Case Western Reserve University,
.Cleveland, OH, USA . The human colon carcinoma
cell line Caco-2 and the human cervical carcinoma
cell line HeLa were obtained from the American type
Culture Collection. All other chemicals were of ana-
lytical grade.
2.2. Cell culture and uptake measurements
SKPT cells and Caco-2 cells were cultured in
 .Dulbecco’s Modified Eagles’srF-12 1:1 medium
and in minimal essential medium, respectively, as
w x w14 xdescribed previously 30,31 . Uptake of C Gly-Sar
in cells was measured with the uptake buffer whose
composition was 25 mM 4-morpholineethanesulfonic
 .  .acid Mes rTris pH 6.0 , 140 mM NaCl, 5.4 mM
KCl, 1.8 mM CaCl , 0.8 mM MgSO , and 5 mM2 4
w xglucose 30,31 . The culture medium was first aspi-
rated from the dish and the cell monolayer was
washed once with 1 ml of the uptake buffer. Uptake
was initiated by the addition of 1 ml of the uptake
buffer containing radiolabeled substrate. Incubation
was continued for 10 min, after which uptake was
terminated by the removal of the medium followed
by three times washing with ice-cold uptake buffer.
The cells were then solubilized with 1 ml of 0.2 M
NaOH, 1% SDS and the contents were transferred to
a counting vial for determination of radioactivity.
2.3. Vaccinia ˝irus expression of PEPT 1 and PEPT
2
This was done using the procedure described ear-
w xlier 32,33 . Subconfluent HeLa cells in 24-well cul-
ture plates were first infected with a recombinant
vaccinia virus VTF which carries the gene for T77-3
RNA polymerase as a part of its genome. This en-
ables the HeLa cells to express T7 RNA polymerase.
Following the infection, the cells were transfected
with pBluescript-PEPT 1 cDNA construct or with
pBluescript-PEPT 2 cDNA construct. In these con-
structs, the cDNAs were under control of T7 pro-
moter in the plasmid. Cells transfected with empty
plasmid served as control. Transfection was mediated
by lipofection. The virus-encoded T7 RNA poly-
merase catalyzes the transcription of the cDNA, al-
lowing transient expression of the PEPT 1 or PEPT 2
protein in the HeLa cell plasma membrane. After 12
h post-infection, transport measurements were made
w14 xat room temperature with C Gly-Sar. The uptake
 .medium was 25 mM MesrTris pH 6.0 containing
140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl , 0.82
mM MgSO , and 5 mM glucose. The time of incuba-4
tion for uptake measurements was 3 min. At the end
of the incubation, the uptake was terminated by
removal of the uptake medium by aspiration followed
by washing two times with ice-cold uptake medium
which did not contain radiolabeled substrate. The
cells were then solubilized with 0.5 ml of 1% SDS,
transferred to counting vials, and used for determina-
tion of radioactivity.
2.4. Preparation of renal brush-border membrane
˝esicles
Brush-border membrane vesicles were prepared
from kidneys by the Mg2q-aggregation method in the
w  .xpresence of ethylene bis oxyethylenenitrilo te-
 . w xtraacetic acid EGTA as described previously 34 .
Kidneys were obtained from two different rat strains,
Sprague-Dawley and SHR. The renal tissue compris-
ing the cortical and outer medullary regions was used
for the isolation of membrane vesicles because we
have shown earlier that both regions possess peptide
w xtransport activity 35 . The tissue was homogenized
in 10 volumes of homogenizing buffer 12 mM
TrisrNaOH, 5 mM EGTA, 300 mM mannitol, pH
.7.5 for 90 s using an Ultra Turrax, with the speed set
at 50. The resulting homogenate was diluted with an
equal volume of ice-cold water. A stock solution of 1
M MgCl was added to the above suspension to give2
a final concentration of 10 mM MgCl . The mixture2
was stirred for 1 min and allowed to stand for 15
min. The suspension was then centrifuged at 3000=g
for 10 min. The pellet was discarded, and the super-
natant was centrifuged again at 60 000=g for 30
min. The pellets containing brush-border membranes
were washed twice with the preloading buffer by
dilution and centrifugation. The preloading buffer
 .was 50 mM 4- 2-hydroxyethyl -1-piperazineethane-
 .  .sulfonic acid Hepes , 75 mM Tris pH 8.3 , contain-
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ing 100 mM K SO . A 25-gauge needle was used to2 4
suspend the pellets. The protein concentration of the
final membrane preparation was adjusted to 6 mgrml,
and it was stored in liquid N in small aliquots until2
use.
2.5. Uptake measurements in membrane ˝esicles
w14 xUptake of C Gly-Sar was measured at room
 . w xtemperature 22–238C as described earlier 36 using
a rapid filtration technique. Millipore membrane fil-
 .ters DAWP type; 0.65 mm pore size were used.
Membrane vesicles were incubated with 50 mM vali-
nomycin prior to use in uptake measurements. Uptake
was initiated by mixing 40 ml of the membrane
suspension with 160 ml of uptake buffer 50 mM
Hepes, 50 mM Mes, 25 mM Tris, 300 mM mannitol,
.pH 6.0 containing radiolabeled peptide substrate. All
uptake measurements were carried out with 10-s in-
cubations. Uptake was terminated by the addition of
3 ml of ice-cold stop buffer 2 mM HepesrTris, 210
.mM KCl, pH 7.5 . The mixture was filtered and the
filter retaining the membrane vesicles was washed
with 3=5 ml of the stop buffer. The washed filter
was transferred to a counting vial, and the radioactiv-
ity associated with the filter was counted by liquid
scintillation spectrometry.
2.6. Oocyte expression and electrophysiological mea-
surements
The procedures for preparation of oocytes from
Xenopus lae˝is, synthesis of human PEPT 1 cRNA,
and microinjection of cRNA into the oocytes have
w xbeen described previously 37,38 . A two-microelec-
w xtrode voltage-clamp system 39 was used to measure
steady-state currents associated with PEPT 1-media-
ted transport at pH 6.0. Step changes in membrane
potential were applied, each for a duration of 100 ms
 .q50 mV to y130 mV in 20 mV increments . The
value for K , the substrate concentration at which0.5
current is half-maximal, was determined by measur-
ing the currents over a ceftibuten concentration range
of 0.05–5 mM and fitting the data to Michaelis-
Menten equation describing a single transport system.
2.7. Data analysis
Experiments were done in duplicate or triplicate
and each experiment was repeated two to three times.
Results are given as means"S.E. The kinetic param-
eters, the Michaelis-Menten constant, K , and thet
maximal velocity, V , were calculated by linearmax
regression of the Eadie-Hofstee plot and confirmed
by nonlinear regression methods using the Fig. P,
version 6.0, computer program.
3. Results and discussion
3.1. Studies with cultured cells which differentially
express PEPT 1 or PEPT 2
Recent molecular cloning studies have established
that the Hq-coupled peptide transporters expressed in
the intestine and kidney are structurally different,
w xencoded by different genes 32,33,37,40–43 . The
 .cloned human intestinal peptide transporter PEPT 1
 .and the human kidney peptide transporter PEPT 2
exhibit only 50% homology in amino acid sequence.
PEPT 1 is expressed primarily in the intestine and, to
a much lesser extent, in the kidney. PEPT 2 is
expressed in the kidney and other tissues such as the
brain, lung, liver and heart but not in the intestine
w x33,43 . Even though both of these transporters cat-
alyze the transport of small peptides in a Hq gradi-
ent-dependent manner, there are important differ-
ences between these transporters in substrate affinity
w x w x40,43,44 as well as in substrate specificity 44 . In
particular, b-lactam antibiotics are differentially rec-
w xognized by PEPT 1 and PEPT 2 44 . We have
identified recently two cultured cell lines, one ex-
pressing PEPT 1 and not PEPT 2 and the other
w xexpressing PEPT 2 and not PEPT 1 44 . These are
the human colon carcinoma cell line Caco-2 PEPT
.1 and the SHR rat kidney proximal tabular cell line
 .SKPT PEPT 2 . These cell lines provide excellent
model systems to differentially study the substrate
selectivity of PEPT 1 and PEPT 2. In the present
study, we have used these two cell lines to investigate
the interaction of anionic cephalosporins with PEPT
1 and PEPT 2. These studies were done with two
 .dianionic cephalosporins cefixime and ceftibuten
 .and one monoanionic cephalosporin cefdinir . The
cells were cultured as confluent monolayers and the
activity of the Hq-coupled peptide transporters was
measured by determining the uptake of the dipeptide
Gly-Sar in the presence of an inwardly directed Hq
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Fig. 1. Chemical structures of Gly-Sar and the anionic
cephalosporins ceftibuten, cefixime, and cefdinir.
gradient. This was done by measuring the uptake
from an extracellular medium of pH 6.0. Gly-Sar was
chosen as the peptide substrate because of its resis-
tance to hydrolysis by membrane-bound peptidases.
The chemical structures of these antibiotics are given
in Fig. 1 for comparison with the chemical structure
of Gly-Sar. Measurements of Gly-Sar uptake in
Caco-2 cells and in SKPT cells were made using an
incubation time of 10 min. The uptake was found to
 .be linear over this incubation period Fig. 2 . We first
investigated the influence of increasing concentra-
tions of the anionic cephalosporins on the uptake of
 .Gly-Sar in these cells Fig. 3 . The activity of the
peptide transporters measured at 5 mM Gly-Sar in the
absence of cephalosporins was 187.4"6.1 pmolrmg
 .of proteinr10 min in Caco-2 cells PEPT 1 and
121.4"1.2 pmolrmg of proteinr10 min in SKPT
 .cells PEPT 2 . All three anionic cephalosporins in-
hibited the peptide transporter activity in both cell
lines to a significant extent. In the case of PEPT 1,
the inhibitory potency was in the following order:
ceftibuten ) cefixime ) cefdinir. The IC values50
i.e., the concentration necessary to cause 50% inhibi-
.tion for these cephalosporins were 0.9"0.1 mM,
;10 mM, and )10 mM respectively. In the case of
 .Fig. 2. Time course of Gly-Sar uptake in Caco-2 cells A and in
 .SKPT cells B at a Gly-Sar concentration of 5 mM.
PEPT 2, the order of the inhibitory potency was the
same as in the case of PEPT 1, i.e., ceftibuten)
cefixime)cefdinir. The IC values were 0.48"50
0.03 mM, 3.2"0.1 mM, and ;10 mM respectively.
Even though the order of the inhibitory potency was
the same, PEPT 2 was comparatively more sensitive
to inhibition by the anionic cephalosporins than PEPT
1. These findings are in agreement with the earlier
observations that PEPT 1 is a low-affinity transporter,
whereas PEPT 2 is a high-affinity transporter
w x32,40,43 . The most important finding from these
w14 xFig. 3. Inhibition of C Gly-Sar uptake by anionic
 .  .cephalosporins in Caco-2 cells A and SKPT cells B . Uptake
w14 xof 5 mM C Gly-Sar was measured for 10 min in monolayer
cultures of Caco-2 cells and SKPT cells at pH 6.0 in the absence
and presence of increasing concentrations of anionic
cephalosporins. Uptake of Gly-Sar measured in the absence of
the inhibitors was taken as 100%. This value was 187.4"6.1
pmolrmg of proteinr10 min for Caco-2 cells and 121.4"1.2
pmolrmg of proteinr10 min for SKPT cells. Key: v, ceftibuten;
‘, cefixime; I, cefdinir.
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experiments is, however, that the anionic
cephalosporins interact with the kidney-specific pep-
tide transporter PEPT 2. This is in contrast to the
w xreport by Tamai et al. 26 but in agreement with the
w xreports by Naasani et al. 27–29 .
There is no controversy with regard to the recogni-
tion of the anionic cephalosporins as substrates by the
intestinal peptide transport system. Our results with
Caco-2 cells also clearly show that cefixime and
ceftibuten interact with PEPT 1. Several earlier stud-
ies, with intestinal brush border membrane vesicles as
well as with Caco-2 cells, have already demonstrated
that the anionic cephalosporins interact with the in-
testinal peptide transporter in a competitive manner
w xwith respect to dipeptide substrates 17,18,21,22 . In
the present study, we investigated the kinetic nature
of the inhibition of Gly-Sar transport mediated by the
kidney-specific peptide transporter PEPT 2 by two of
the anionic cephalosporins, namely cefixime and
ceftibuten. Gly-Sar uptake was measured over the
concentration range of 25–500 mM in the absence or
in the presence of the cephalosporins. The concentra-
tions of the cephalosporins chosen for these studies
were approximately equal to the IC values50
 .ceftibuten, 0.5 mM; cefixime, 3 mM . Fig. 4A de-
scribes the relationship between the uptake rate and
 w x.Gly-Sar concentration v versus S . The values for v
given in Fig. 4A represent the rates of total uptake
and have not been corrected for the nonsaturable
diffusional component. Analysis of the kinetic param-
eters of the uptake process was, however, done only
for the saturable component. For this purpose, the
diffusional component of Gly-Sar uptake was deter-
mined by measuring the uptake in the presence of
 .excess Gly-Pro 10 mM , a competing substrate for
the peptide transport process. The diffusional compo-
nent represented 4% of total uptake at 25 mM Gly-Sar
and 18% of total uptake at 500 mM Gly-Sar. Fig. 4B
describes the data for saturable component given as
Eadie-Hofstee plots. For control Gly-Sar uptake as
well as for Gly-Sar uptake measured in the presence
of ceftibuten or cefixime, the Eadie-Hofstee plots
 2 .were linear r )0.98 , indicating participation of a
single transport system in Gly-Sar uptake. In the
absence of the cephalosporins, the Michaelis-Menten
constant, K , for Gly-Sar was 74.5"2.9 mM and thet
maximal velocity, V , was 1.77"0.02 nmolrmgmax
of proteinr10 min. These values agree well with the
Fig. 4. Kinetics of inhibition of Gly-Sar uptake by cefixime and
ceftibuten in SKPT cells. Uptake of Gly-Sar was measured in
 .monolayer cultures of SKPT cells in the absence ‘ or presence
 .  .of 3 mM cefixime v or 0.5 mM ceftibuten B . The uptake
was measured at pH 6.0 with a 10-min incubation period. Con-
centration of Gly-Sar was varied between 25 and 500 mM,
w14 xkeeping the concentration of C Gly-Sar constant at 5 mM and
adding unlabeled Gly-Sar to desired concentrations. Non-media-
ted component was determined from the uptake of radiolabel
measured in the presence of 10 mM Gly-Pro. This component
was subtracted from total uptake to calculate mediated uptake
which was used in kinetic analysis. Results are given as uptake
 .rate versus Gly-Sar concentration A and as Eadie-Hofstee plots
 . w xB For v versus s plots, uptake rates without correction for the
diffusional component were used and for Eadie-Hofstee plots,
uptake rates after correction for the diffusional component were
used.
w xpreviously reported values 31,44 . The correspond-
ing values in the presence of the anionic
cephalosporins were 135.3"3.7 mM and 1.58"0.02
nmolrmg of proteinr10 min in the case of cefixime
and 188.0"11.6 mM and 1.78"0.05 nmolrmg of
proteinr10 min in the case of ceftibuten. In both
cases, the presence of the cephalosporins increased
the K value for Gly-Sar by about 2-fold. The Vt max
remained unaffected. These results show that ce-
fixime and ceftibuten inhibit the PEPT 2-mediated
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Fig. 5. Determination of inhibition constants by Dixon plots.
Uptake of Gly-Sar was measured in monolayer cultures of Caco-2
 .  .cells A and SKPT cells B with a 10 min incubation. For
Caco-2 cells, uptake was measured at Gly-Sar concentration of
 .  .50 mM ‘ and 500 mM v in the presence of increasing
 .concentrations of ceftibuten 0–2.5 mM . For SKPT cells, uptake
 .was measured at Gly-Sar concentrations of 10 mM ‘ and 70
 .mM v in the presence of increasing concentrations of ceftibuten
 .0.1–2 mM . The diffusional component, measured in the pres-
ence of excess amount of Gly-Pro 50 mM for Caco-2 cells and
.10 mM for SKPT cells , was subtracted from total uptake to
 .calculate mediated uptake. V, nmolrmg of proteinr10 min .
Gly-Sar uptake competitively. Thus, the interaction
of the anionic cephalosporins with the renal peptide
 .transporter PEPT 2 is kinetically similar to that with
 .the intestinal peptide transporter PEPT 1 .
We have also determined the inhibition constants
 .K for ceftibuten, the most potent anionici
cephalosporin to inhibit Gly-Sar uptake by PEPT1
and by PEPT2. This was done by measuring medi-
ated uptake of Gly-Sar in Caco-2 cells and in SKPT
cells at two different Gly-Sar concentrations 50 mM
and 500 mM for Caco-2 cells; 10 mM and 70 mM
.for SKPT cells in the presence of increasing concen-
 .trations of ceftibuten 0–2.5 mM . The results are
given as Dixon plots 1ruptake rate versus inhibitor
.concentration . The plots were linear at both Gly-Sar
 .concentrations in Caco-2 cells Fig. 5A as well as in
 .SKPT cells Fig. 5B , and the lines intersected above
the abscissa in the fourth quadrant in both cells, as
expected from the competitive nature of the inhibi-
tion of Gly-Sar uptake by ceftibuten. The K valuesi
were calculated from the points of intersection. The
K value was 0.87 mM for Caco-2 cells and 0.38i
mM for SKPT cells. These values are similar to be
corresponding K values 0.89 mM and 0.45 mM,i
.respectively calculated from the IC data in Fig. 350
w xby the method of Cheng and Prusoff 45 using the
w xK value of 1.1 mM for Caco-2 cells 30 and 75 mMt
 .for SKPT cells present study .
3.2. Studies with the cloned human intestinal and
renal peptide transporters, PEPT 1 and PEPT 2
The SKPT cell line which expresses PEPT 2 is of
rat kidney origin. There is no human kidney cell line
known to express PEPT 2. Even though the studies
thus far described have shown that anionic
cephalosporins interact with PEPT 2 present in the
SKPT cells, it is important to know whether such
interaction also occurs in the case of the human
kidney peptide transporter. We have recently isolated
the cDNA which codes for the human kidney-specific
w xpeptide transporter 33 . This cDNA can be function-
ally expressed in HeLa cells using the vaccinia virus
w xexpression system 33,40,44 . HeLa cells are ideal for
these studies because there is no endogenous peptide
transport activity in these cells. After functional ex-
pression of the human PEPT 2 cDNA in HeLa cells,
the cells were used to study the interaction of anionic
 .cephalosporins with PEPT 2 Fig. 6 . In control cells,
transfected with pBluescript vector alone, the peptide
transport activity measured as Gly-Sar uptake at a
concentration of 50 mM was 17.3"0.5 pmolr106
cellsr3 min. This uptake was entirely due to nonsat-
urable diffusional process. The transport activity in-
creased 4-fold to 65.4"1.6 pmolr106 cellsr3 min
in cells transfected with pBluescript-PEPT 2 cDNA
construct. The difference between these two values
represented the PEPT 2-mediated activity. This PEPT
2-specific Gly-Sar uptake activity was found to be
inhibited to a significant extent by anionic
cephalosporins. At a concentration of 10 mM, the
inhibition of Gly-Sar uptake caused by cefixime,
ceftibuten, and cefdinir was 54%, 96% and 48%
 .respectively Fig. 6 . These data clearly demonstrate
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Fig. 6. Influence of anionic cephalosporins on Gly-Sar uptake mediated by the cloned human kidney peptide transporter PEPT 2. HeLa
 .cells were transfected with either empty pBluescript alone pBS or with PEPT 2 cDNA. The cDNA was functionally expressed in these
cells by the vaccinia virus expression system. Uptake of 50 mM Gly-Sar was measured in these cells at pH 6.0 with a 3-min incubation.
 .  .A Gly-Sar uptake in control and in PEPT 2-expressing cells. B PEPT 2-mediated Gly-Sar uptake in the absence or presence of anionic
 . 6cephalosporins 10 mM , given as percent of uptake measured in the absence of the inhibitors. The 100% value was 47.9"1.3 pmolr10
cellsr3 min.
Fig. 7. Influence of anionic cephalosporins on Gly-Sar uptake mediated by the cloned human intestinal peptide transporter PEPT 1. HeLa
 .cells were transfected with either empty pBluescript alone pBS or with PEPT 1 cDNA. The cDNA was functionally expressed in these
cells by the vaccinia virus expression system. Uptake of 20 mM Gly-Sar was measured in these cells at pH 6.0 with a 3-min incubation.
 .  .A Gly-Sar uptake in control and in PEPT 1-expressing cells. B PEPT 1-mediated Gly-Sar uptake in the absence or presence of anionic
 . 6cephalosporins 10 mM , given as percent of uptake measured in the absence of the inhibitors. The 100% value was 217"25 pmolr10
cellsr3 min.
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Fig. 8. Dose-response relationship for the inhibition of PEPT 1-
and PEPT 2-mediated Gly-Sar uptake by ceftibuten. HeLa cells
 .were transfected with either PEPT 1 cDNA v or PEPT 2
 .cDNA ‘ . The cDNAs were functionally expressed in these
cells by the vaccinia virus expression system. Uptake of Gly-Sar
was measured with a 3-min incubation. Concentration of Gly-Sar
was 20 mM for PEPT 1 and 40 mM for PEPT 2. Concentration
of ceftibuten was varied between 0 and 10 mM. Uptake measured
in cells transfected with empty pBluescript was subtracted from
uptake measured in cDNA-transfected cells to determine cDNA-
specific uptake. Results are given as percent of uptake measured
in the absence of ceftibuten. The 100% value was 144"10
pmolr106 cellsr3 min for PEPT 1 and 31"4 pmolr106 cellsr3
min for PEPT 2.
that anionic cephalosporins interact with the human
kidney peptide transporter PEPT 2.
We also studied the interaction of anionic
cephalosporins with the human intestinal peptide
transporter under similar conditions. The human PEPT
1 cDNA was functionally expressed in HeLa cells
using the vaccinia virus expression system. Gly-Sar
uptake measured at a concentration of 20 mM was
9.8"1.4 pmolr106 cellsr3 min in HeLa cells trans-
fected with pBluescript vector alone. This value in-
creased 23-fold to 227.3"26.0 pmolr106 cellsr3
min in cells transfected with pBluescript-PEPT 1
 .cDNA construct Fig. 7 . The PEPT 1-specific Gly-
Sar uptake was found to be inhibited by 44%, 87%,
and 31% in the presence of cefixime, ceftibuten, and
 .cefdinir 10 mM each respectively. Thus, anionic
cephalosporins are recognized by human PEPT 1 and
human PEPT 2.
Fig. 8 describes the dose-response relationship for
the inhibition of PEPT 1- and PEPT 2-mediated
Gly-Sar uptake by ceftibuten, the most potent in-
hibitor among the anionic cephalosporins tested in
this study. The concentration of Gly-Sar was 20 mM
for PEPT 1 and 40 mM for PEPT 2. The IC value50
for the inhibition was found to be 0.76"0.13 mM
for PEPT 1 and 0.14"0.01 mM for PEPT 2. The
corresponding K values were calculated from thesei
IC values according to the method of Cheng and50
w xPrusoff 45 . The K value used in this calculationt
w xwas 0.29 mM for PEPT 1 32 and 74 mM for PEPT
w x2 40 . These K values were determined undert
experimental conditions similar to those used in the
present study. The K value for the inhibition ofi
Gly-Sar uptake by ceftibuten was 0.71"0.12 mM
for PEPT 1 and 0.09"0.01 mM for PEPT 2.
3.3. Studies with brush border membrane ˝esicles
isolated from rat kidney
w xThe studies by Tamai et al. 26 which showed no
interaction of cefixime with the renal peptide trans-
porter were done with brush border membrane vesi-
cles isolated from Sprague-Dawley rat kidneys. The
Fig. 9. Influence of cefixime and ceftibuten on Gly-Sar uptake in
brush border membrane vesicles isolated from Sprague-Dawley
 .  .  .A and SHR B rat kidneys. Uptake of Gly-Sar 30 mM was
measured in these vesicles in the presence of an inwardly di-
rected Hq gradient and an inside-negative Kq-diffusion potential
with a 10-s incubation. When present, the concentration of
cefixime was 10 mM and that of ceftibuten was 2.5 mM. Results
are given as percent of uptake measured in the absence of
 .inhibitors control . The 100% value was 104.5"1.6 pmolrmg
of proteinr10 s in Sprague-Dawley rats and 76.0"1.3 pmolrmg
of proteinr10 s in SHR rats.
( )M.E. Ganapathy et al.rBiochimica et Biophysica Acta 1324 1997 296–308 305
studies described thus far in this paper were done
either with SKPT cells which originated from SHR
rat kidney or with the cloned human PEPT 2. In order
to find out whether species andror animal strain
differences might have contributed to the varying
results obtained in these studies, we investigated the
interaction of anionic cephalosporins with the renal
peptide transporter using brush border membrane
vesicles prepared from Sprague-Dawley rat kidneys
 .and from SHR rat kidneys Fig. 9 . Gly-Sar uptake in
these membrane vesicles were measured in the pres-
ence of an inwardly directed Hq gradient and a
valinomycin-induced inside-negative Kq-diffusion
potential. The Gly-Sar uptake activity was slightly
higher in Sprague-Dawley rat kidney membrane vesi-
cles than in SHR rat kidney membrane vesicles. At a
Gly-Sar concentration of 30 mM, the uptake activity
was 104.5 " 1.6 pmolrmg of proteinr10 s in
Sprague-Dawley rats and 76.0"1.3 pmolrmg of
proteinr10 s in SHR rats. Cefixime and ceftibuten
inhibited the Gly-Sar uptake activity significantly in
both rat strains. There was no difference in the extent
of inhibition between Sprague-Dawley and SHR rats.
In both rat strains, the inhibition caused by 10 mM
cefixime was about 30%. Ceftibuten was consider-
ably more potent than cefixime in inhibiting Gly-Sar
uptake. The inhibition caused by 2.5 mM ceftibuten
was about 35%.
There was a significant quantitative difference in
the inhibitory potency of the anionic cephalosporins
between SKPT cells and SHR rat kidney brush bor-
der membrane vesicles. This difference is not ex-
plainable on the basis of animal species or animal
strain differences because SKPT cells were originally
derived from SHR rat kidney. The data show that the
anionic cephalosporins are more potent in inhibiting
Gly-Sar uptake in SKPT cells than in isolated renal
brush border membrane vesicles. Intact cells are
metabolically active and maintain stable intracellular
 q .pH hence transmembrane H gradient and mem-
brane potential. Furthermore, Gly-Sar uptake is linear
in intact cells over the time period of uptake mea-
surement. In contrast, isolated brush border mem-
brane vesicles cannot maintain the experimentally
imposed transmembrane Hq gradients and membrane
potential. Even with an incubation period as short as
10 s, Gly-Sar uptake is not linear. Another factor is
the concentration of Gly-Sar used in these studies. In
SKPT cells, Gly-Sar concentration was 5 mM which
is almost 15-fold less than the Michaelis-Menten
constant. On the other hand, Gly-Sar concentration
was 30 mM when renal brush border membrane
vesicles were employed. These factors are most likely
responsible for the relatively lesser potency of the
anionic cephalosporins in inhibiting Gly-Sar uptake
in membrane vesicles than in intact cells.
3.4. Studies of ceftibuten transport in Xenopus oocytes
expressing human PEPT 1
Several studies have investigated the transport of
the anionic cephalosporin cefixime via the peptide
transport system in intestinal brush border membrane
w xvesicles 17,19,21 . These investigations have pro-
vided unequivocal evidence for the involvement of
 .the intestinal peptide transporter PEPT 1 in the
transport of cefixime. However, in contrast to several
peptide substrates whose transport via PEPT 1 is
known to be associated with the transfer of positive
charge across the membrane, the transport of ce-
fixime was interestingly found to be associated with
w xthe transfer of negative charge 17 . Such a transport
mechanism would render the PEPT 1-mediated trans-
port of anionic cephalosporins unfavorable in the
intestine because of the presence of an inside-nega-
tive membrane potential across the brush border
membrane. Therefore, we investigated the issue of
charge transfer associated with PEPT 1-mediated
transport of the anionic cephalosporin ceftibuten in
Xenopus oocytes expressing human PEPT 1. These
oocytes are readily amenable for direct measurements
of transport-associated charge transfer using electro-
physiological means. In this approach, the oocyte is
voltage-clamped and transport-associated changes in
membrane potential are compensated by passing cur-
rents of appropriate polarity and magnitude to main-
tain the membrane potential at the clamped level.
This current is the measured parameter of transport.
This experimental approach provides direct informa-
tion on the nature of charge transfer associated with a
 .transport process. In control water-injected oocytes,
ceftibuten-evoked currents were not detectable, indi-
cating the absence of endogenous electrogenic
ceftibuten transport pathways in Xenopus oocytes.
However, in oocytes expressing human PEPT 1, pH-
dependent, ceftibuten-evoked currents were readily
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Fig. 10. Ceftibuten-evoked currents in an oocyte expressing
 .hPEPT 1. A pH-dependence of the ceftibuten-evoked current.
 .The oocyte was clamped at a membrane potential V of y50m
mV and current continuously monitored while superfusing test
solutions for the periods indicated in the top panel. Ceftibuten
 .CB, solid bars was superfused at 5 mM in 100 mM NaCl
 .  .medium at pH 7.5 diagonal hatch and at pH 6.0 shaded bar .
Each time, ceftibuten was washed out with substrate-free medium
 .  .at pH 7.5 the current trace has been corrected for drift . B
currentrvoltage relationship of the 5 mM ceftibuten-evoked cur-
 .rents I .
 .observed Fig. 10A . At pH 7.5, 5 mM ceftibuten
evoked a tiny outward current, showing that PEPT
1-mediated ceftibuten transport is indeed associated
with the transfer of negative charge under these
conditions. But, at pH 6.0, 5 mM ceftibuten evoked
marked inward current which shows that PEPT 1-
mediated ceftibuten transport in the presence of a Hq
gradient is associated with the transfer of positive
charge. It appears that, in the absence of a Hq
gradient, transport of the anionic substrate uncoupled
from Hq may occur via PEPT 1 to some extent. The
ceftibuten-evoked currents at pH 6.0 were concentra-
tion-dependent and obeyed Michaelis-Menten kinet-
ics. The K substrate concentration at which cur-0.5
.rent was half-maximal for ceftibuten was 0.4"0.1
 .mM at y50 mV data not shown . The current-volt-
 .age relationship for 5 mM saturating ceftibuten
 .Fig. 10B was qualitatively similar to that for the
w xzwitterionic peptide Gly-Sar 38 or for the zwitteri-
w xonic cephalosporin cefadroxil 41 . The ceftibuten-
evoked currents displayed a non-linear dependence
upon membrane potential, with no reversal of cur-
rents at depolarized membrane potential up to q50
.mV and no indication of saturating with hyperpolar-
 .ization up to y 130 mV .
We were unable to perform similar electrophysio-
logical studies with PEPT 2 because injection of
human PEPT 2 cRNA into oocytes failed to generate
detectable currents. The human PEPT 2 cDNA is
functional as evident from the cDNA-induced Gly-Sar
uptake in HeLa cells. The reasons for the inability of
the PEPT 2 cRNA to be functionally expressed in
oocytes measured either by tracer uptake or by the
electrophysiological approach are not known. The
human PEPT 2 cDNA has a truncated 3X non-coding
 .region and lacks a poly A tail and it is possible that
this compromises the stability of the cRNA in the
oocytes. The recently cloned rabbit PEPT 2 cDNA
 .possesses a poly A tail and the injection of the
cRNA derived from this cDNA has been shown to
lead to the functional expression of the peptide trans-
porter as detected by the electrophysiological ap-
w xproach 43 .
In conclusion, the present study has provided un-
equivocal evidence for the interaction of anionic
cephalosporins with the intestinal and renal
Hqrpeptide cotransporters. We have documented this
interaction using four different approaches. This in-
vestigation has produced several important findings.
The results of this investigation demonstrate for the
first time that the human PEPT 1 cloned from normal
intestine can transport anionic cephalosporins, thus
corroborating the observations in the human colon
carcinoma cell line Caco-2. This study also estab-
lishes definitively that the renal peptide transporter
interacts with anionic cephalosporins. The interaction
is documented with cultured rat kidney cells which
exclusively express PEPT 2, with the human PEPT 2
cloned from kidney, and with rat renal brush border
membrane vesicles. The present study also shows
using direct electrophysiological approaches that
ceftibuten transport mediated by human intestinal
peptide transporter PEPT 1 in the presence of an
inwardly directed Hq gradient is associated with
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transfer of positive charge. Further experiments aimed
at determining the Hqrceftibuten coupling ratio and
 -the possible involvement of other ions e.g., OH and
q.K as additional cotransported substrates are needed
to elucidate the molecular mechanism responsible for
this charge transfer.
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